Key word there: "scientific debate." Not "public newspaper debate."
The non-random arm—missing dose in the real world—can give signal to stop randomized trial while not being good enough to green-light. (Part of my conceptual model here is how UK/NHS turned the kitchen sink clinical phase into randomized trials and we got dexa out of that).
-
-
Yep, all good points. But the data in both trials say that 1 dose doesn’t produce a potent response. So the prudent move would be to keep using 2 doses until a trial shows otherwise? If the rollout switched to 1 dose now and it didn’t work, then we’ve wasted the early supply?pic.twitter.com/5wAdSjbDGB
-
Of course. In fact, one of the motivations for getting ahead of this by calling for a trial/study is that there are powerful politicians already advocating for this *without a trial.* Also some people may be denied a vaccine till 2022 due to shortage.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.